Angle PLC ANGLE notice of interim results (2793J)
2023年8月15日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMAGL
RNS Number : 2793J
Angle PLC
15 August 2023
For immediate release 15 August 2023
ANGLE plc ("the Company")
Notice of Interim Results and Webcast
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company with innovative CTC diagnostic solutions for the research
and diagnostic oncology market, will be releasing its interim
results for the six months ended 30 June 2023 on Thursday 7
September 2023.
A meeting for analysts will be held at 11:00 am BST on Thursday
7 September 2023 at the offices of FTI Consulting, 200 Aldersgate,
Aldersgate Street, London EC1A 4HD.
A live webcast of the analyst meeting can be accessed via
ANGLE's Investor Centre page,
https://angleplc.com/investor-relations/corporate-presentations/ ,
with Q&A participation reserved for analysts only. Please
register in advance and log on to the webcast approximately 5
minutes before 11:00 am on the day of the results. A recording of
the webcast will be made available on ANGLE's website following the
results meeting.
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800
Jefferies (Joint Broker)
Thomas Bective, Shaam Vora +44 (0) 20 7029 8000
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative
CTC diagnostic solutions for the research and diagnostic oncology
market using a simple blood sample. ANGLE's FDA cleared and patent
protected circulating tumor cell (CTC) harvesting technology known
as the Parsortix(R) system enables complete analysis of the sample
including whole cell imaging and proteomic analysis and full
genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic
products and clinical services. Diagnostic products include the
Parsortix(R) system and associated consumables. The clinical
services business is offered through ANGLE's GCP-compliant
laboratories in the UK and the United States. Services include
custom made assay development and clinical trial testing for
pharma.
Over 80 peer-reviewed publications have demonstrated the
performance of the Parsortix system. For more information, visit
www.angleplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORPIMFTMTTBBRJ
(END) Dow Jones Newswires
August 15, 2023 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
過去 株価チャート
から 4 2024 まで 5 2024
Angle (LSE:AGL)
過去 株価チャート
から 5 2023 まで 5 2024